

AMENDMENT TO THE CLAIMS (CORRECTED)

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims

Claims 1-22 (Canceled)

23. (Currently amended) A radially expandable tape-reinforced tubular vascular graft, comprising:
a tubular PTFE base graft; and
a reinforcing tape wrapped around the tubular base graft,
wherein the radially expandable tape-reinforced tubular graft is capable of undergoing radial enlargement of greater than 5 % to increase its diameter without breaking or tearing of the reinforcing tape.
24. (Previously presented) The radially expandable tape-reinforced tubular vascular graft of claim 23, wherein the tubular PTFE base graft comprises a sintered, longitudinally expanded tubular PTFE extrudate.
25. (Canceled)
26. (Canceled)
27. (Previously presented) The radially expandable tape-reinforced tubular vascular graft of claim 24, wherein the tubular PTFE extrudate is longitudinally expanded by an expansion ratio of more than about two to one.
28. (Canceled)
29. (Currently Amended) A radially expandable tape-reinforced tubular vascular graft comprising:
a tubular PTFE base graft that has been radially reduced in size from an expanded diameter to a reduced diameter; and
a reinforcing tape reduced in size from an expanded porosity to a reduced porosity,
wherein the reinforcing tape is wrapped around the tubular PTFE base graft and wherein the radially expandable tape-reinforced tubular graft is capable of undergoing radial

enlargement of greater than 5 % to increase its diameter without breaking or tearing of the reinforcing tape.

30. (Canceled)

31. (Canceled)

El
contd

32. (Currently Amended) The radially expandable tape-reinforced tubular vascular graft of claim 30 29, wherein the ~~radially expandable tape-reinforced tubular vascular graft is capable of undergoing radial enlargement to increase its diameter by at least 5%~~ tubular PTFE base graft comprises a sintered, longitudinally expanded tubular PTFE extrudate.

If an appropriate payment does not accompany or precede this submission, the Commissioner is hereby authorized to charge any required fees, such as under 37 C.F.R. §§.1.16 or 1.17, including any petition for extension of time, or to credit any overpayment, to Deposit Account No. 50-1225.

Dated: October 10, 2003

Respectfully submitted,

Edwards Lifesciences LLC

By: 

Rajiv Yadav, Ph.D., Esq.

Registration No. 43,999

Edwards Lifesciences LLC

Law Department

One Edwards Way

Irvine, California 92614

Telephone: (949) 250-6801

Facsimile: (949) 250-6850

Customer No. 30452